Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
8 11 Search
2025
Evaluating Sorafenib (SORA-2) as Second-Line Treatment for Unresectable Hepatocellular Carcinoma: A European Retrospective Multicenter Study
Cancers
2023
Real-world comparison of pembrolizumab and nivolumab in advanced hepatocellular carcinoma
BMC Cancer
2023
Treatment options for unresectable hepatocellular carcinoma with hepatitis virus infection following sorafenib failure
Cancer Immunology, Immunotherapy
2022
Efficient multiple treatments including molecular targeting agents in a case of recurrent hepatocellular carcinoma, post-living donor liver transplantation
Clinical Journal of Gastroenterology
2022
The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab
Cancers
2022
Lenvatinib as second-line treatment in patients with unresectable hepatocellular carcinoma: A retrospective analysis
Frontiers in Oncology
2021
Evaluating the Effect of Lenvatinib on Sorafenib-Resistant Hepatocellular Carcinoma Cells
International Journal of Molecular Sciences
2021
Efficacy and Safety of Lenvatinib in Hepatocellular Carcinoma Patients with Liver Transplantation: A Case-Control Study
Cancers
Additional cited-by details will be shown when available from Crossref